Xbira 250 mg Tablet

Product Details

Xbira 250 mg Tablet contains abiraterone acetate, a medication used in the treatment of prostate cancer. It works by inhibiting the production of androgens (male hormones) which can promote the growth of cancer cells.

Uses

• Metastatic Castration-Resistant Prostate Cancer (mCRPC): Xbira is used in combination with other medications like prednisone for treating prostate cancer that has spread beyond the prostate and is resistant to traditional hormonal therapies.
• Metastatic High-Risk Castration-Sensitive Prostate Cancer (mHSPC): Often prescribed alongside androgen deprivation therapy (ADT) for this type of cancer.

How Xbira Works

Abiraterone works by inhibiting CYP17, an enzyme necessary for androgen production. This reduction in androgen levels helps slow down or stop the growth of prostate cancer cells that rely on these hormones to grow and spread.

Common Side Effects

• Fatigue
• Joint or muscle pain
• High blood pressure
• Low potassium levels (hypokalemia)
• Fluid retention and swelling

Serious Side Effects (Seek Immediate Medical Attention)

• Severe liver dysfunction
• Adrenal insufficiency
• Increased risk of infections
• Severe allergic reactions

Key Features

• Contains abiraterone acetate, a potent CYP17 inhibitor for prostate cancer.
• Reduces androgen production to slow the progression of cancer.
• Effective as part of combination therapy for metastatic prostate cancer.

Frequently Asked Questions (FAQ)

1. How should I take Xbira 250 mg Tablet?
   Take the tablet on an empty stomach, at least 1 hour before or 2 hours after food. Follow your healthcare provider’s instructions on dosing and any combination therapy.
2. Is Xbira safe during pregnancy?
   No, Xbira is not intended for use in women, and it is contraindicated in pregnancy due to risks of fetal harm.
3. Can I continue other medications while on Xbira?
   Inform your healthcare provider about all medications you are taking, as certain drugs may interact with abiraterone.

References

1. National Cancer Institute – Abiraterone Information
   Available from: https://medlineplus.gov/druginfo/meds/a611046.html
2. European Medicines Agency (EMA) – Abiraterone
   Available from: https://go.drugbank.com/drugs/DB05812